Andrea B Apolo
National Cancer Institute (NCI) · Alliance for Clinical Trials in Oncology · National Cancer Institute LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
16
all conditions, ClinicalTrials.gov
NIH grants tied to them
3
NIH RePORTER
Trial papers
31
PubMed author-name match
Trials
Studies that name Andrea B Apolo as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:36 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06228066 · Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)National Cancer Institute (NCI) · recruiting · Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract · principal investigator
- Ph2NCT06161532 · Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...National Cancer Institute (NCI) · recruiting · Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder · principal investigator
- Ph2NCT06041503 · Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)National Cancer Institute (NCI) · recruiting · Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Testicular Germ Cell Tumors · principal investigator
- N/ANCT04923178 · A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract MalignanciesNational Cancer Institute (NCI) · recruiting · Urothelial Cancer, Bladder Cancer, Genitourinary Cancer · principal investigator
- Ph2NCT04501094 · A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial CarcinomaNational Cancer Institute (NCI) · terminated · Urothelial Cancer · principal investigator
- Ph1NCT04235777 · Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary MalignanciesNational Cancer Institute (NCI) · active not recruiting · Urothelial Cancer, Bladder Cancer, Genitourinary Cancer · principal investigator
- Ph2NCT03866382 · Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNational Cancer Institute (NCI) · recruiting · Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma · principal investigator
- Ph2NCT03375307 · Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic ChangesNational Cancer Institute (NCI) · active not recruiting · Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma · principal investigator
- N/ANCT03327883 · Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder CancerNational Cancer Institute (NCI) · completed · Bladder Cancer · principal investigator
- Ph3NCT03244384 · Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial CancerNational Cancer Institute (NCI) · active not recruiting · Localized Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma · principal investigator
- Ph2NCT02788201 · Genomic Based Assignment of Therapy in Advanced Urothelial CarcinomaNational Cancer Institute (NCI) · completed · Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms · principal investigator
- Ph1NCT02496208 · Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsNational Cancer Institute (NCI) · active not recruiting · Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma · principal investigator
- Ph2NCT01967576 · Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/ParagangliomaNational Cancer Institute (NCI) · completed · Pheochromocytoma, Paraganglioma · principal investigator
- Ph2NCT01688999 · Cabozantinib for Advanced Urothelial CancerNational Cancer Institute (NCI) · completed · Urothelial Carcinoma, Urethral Neoplasms, Urinary Bladder Neoplasms · principal investigator
- Ph1NCT01352962 · Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid TumorsNational Cancer Institute (NCI) · completed · Urethral Neoplasms, Neoplasms, Urethral, Cancer of the Urethra · principal investigator
- Ph2NCT01328574 · TRC105 in Adults With Advanced/Metastatic Urothelial CarcinomaNational Cancer Institute (NCI) · completed · Urothelial Carcinoma, Ureteral Neoplasms, Ureter Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Bladder Cancer ProgramZIABC011351 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2010 to 2025 · $1,060,475 awarded in 2025Same name and institution; not confirmed by an ID
- Rare genitourinary tumors projectsZIABC011928 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2019 to 2025 · $1,193,036 awarded in 2025Same name and institution; not confirmed by an ID
- Targeting the MET Pathway in Urothelial CarcinomaZIABC011594 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2014 to 2025 · $397,679 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT03866382, NCT03244384
- The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials NetworkUM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON, Narendranath Epperla · fiscal years 2014 to 2026Named on NCT02496208
- Wisconsin and New Jersey Alliance in Precision Experimental TherapeuticsUM1CA186716 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI Salma Jabbour, GLENN LIU · fiscal years 2014 to 2019Named on NCT02496208
- Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTNUM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI A. Dimitrios Colevas, Alexey V. Danilov, PRIMO N. LARA, HEINZ JOSEF LENZ · fiscal years 2014 to 2026Named on NCT02496208
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:36 UTC. The ranking covers the 200 most relevant of 31 PubMed records, and a shared surname and initials can bring in a namesake. All 31 on PubMed
- 1,521 citationsRCR 81.5
- Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.J Clin Oncol · 2017486 citationsRCR 15.1
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.Lancet Oncol · 2018473 citationsRCR 15.1
- 279 citationsRCR 17.7
- Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.N Engl J Med · 2025147 citationsRCR 31.0
- Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors.J Clin Oncol · 2020112 citationsRCR 4.2
- Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.J Clin Oncol · 2023105 citationsRCR 9.5
- 102 citationsRCR 10.9
- Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.J Clin Oncol · 201388 citationsRCR 2.3
- 80 citationsRCR 4.7